Cargando…

Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds

BACKGROUND: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop cancer despite testing negative for the family’s pathogenic variant. These families may have additional genetic variants, which not only may increase the susceptibility of the families’ path_BRCA1/2, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dominguez-Valentin, Mev, Evans, D. Gareth R., Nakken, Sigve, Tubeuf, Hélène, Vodak, Daniel, Ekstrøm, Per Olaf, Nissen, Anke M., Morak, Monika, Holinski-Feder, Elke, Martins, Alexandra, Møller, Pål, Hovig, Eivind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769521/
https://www.ncbi.nlm.nih.gov/pubmed/29371908
http://dx.doi.org/10.1186/s13053-018-0086-0
_version_ 1783292911808413696
author Dominguez-Valentin, Mev
Evans, D. Gareth R.
Nakken, Sigve
Tubeuf, Hélène
Vodak, Daniel
Ekstrøm, Per Olaf
Nissen, Anke M.
Morak, Monika
Holinski-Feder, Elke
Martins, Alexandra
Møller, Pål
Hovig, Eivind
author_facet Dominguez-Valentin, Mev
Evans, D. Gareth R.
Nakken, Sigve
Tubeuf, Hélène
Vodak, Daniel
Ekstrøm, Per Olaf
Nissen, Anke M.
Morak, Monika
Holinski-Feder, Elke
Martins, Alexandra
Møller, Pål
Hovig, Eivind
author_sort Dominguez-Valentin, Mev
collection PubMed
description BACKGROUND: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop cancer despite testing negative for the family’s pathogenic variant. These families may have additional genetic variants, which not only may increase the susceptibility of the families’ path_BRCA1/2, but also be capable of causing cancer in the absence of the path_BRCA1/2 variants. We aimed to identify novel genetic variants in prospectively detected breast cancer (BC) or gynecological cancer cases tested negative for their families’ pathogenic BRCA1/2 variant (path_BRCA1 or path_BRCA2). METHODS: Women with BC or gynecological cancer who had tested negative for path_BRCA1 or path_BRCA2 variants were included. Forty-four cancer susceptibility genes were screened for genetic variation through a targeted amplicon-based sequencing assay. Protein- and RNA splicing-dedicated in silico analyses were performed for all variants of unknown significance (VUS). Variants predicted as the ones most likely affecting pre-mRNA splicing were experimentally analyzed in a minigene assay. RESULTS: We identified 48 women who were tested negative for their family’s path_BRCA1 (n = 13) or path_BRCA2 (n = 35) variants. Pathogenic variants in the ATM, BRCA2, MSH6 and MUTYH genes were found in 10% (5/48) of the cases, of whom 15% (2/13) were from path_BRCA1 and 9% (3/35) from path_BRCA2 families. Out of the 26 unique VUS, 3 (12%) were predicted to affect RNA splicing (APC c.721G > A, MAP3K1 c.764A > G and MSH2 c.815C > T). However, by using a minigene, assay we here show that APC c.721G > A does not cause a splicing defect, similarly to what has been recently reported for the MAP3K1 c.764A > G. The MSH2 c.815C > T was previously described as causing partial exon skipping and it was identified in this work together with the path_BRCA2 c.9382C > T (p.R3128X). CONCLUSION: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13053-018-0086-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5769521
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57695212018-01-25 Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds Dominguez-Valentin, Mev Evans, D. Gareth R. Nakken, Sigve Tubeuf, Hélène Vodak, Daniel Ekstrøm, Per Olaf Nissen, Anke M. Morak, Monika Holinski-Feder, Elke Martins, Alexandra Møller, Pål Hovig, Eivind Hered Cancer Clin Pract Research BACKGROUND: In kindreds carrying path_BRCA1/2 variants, some women in these families will develop cancer despite testing negative for the family’s pathogenic variant. These families may have additional genetic variants, which not only may increase the susceptibility of the families’ path_BRCA1/2, but also be capable of causing cancer in the absence of the path_BRCA1/2 variants. We aimed to identify novel genetic variants in prospectively detected breast cancer (BC) or gynecological cancer cases tested negative for their families’ pathogenic BRCA1/2 variant (path_BRCA1 or path_BRCA2). METHODS: Women with BC or gynecological cancer who had tested negative for path_BRCA1 or path_BRCA2 variants were included. Forty-four cancer susceptibility genes were screened for genetic variation through a targeted amplicon-based sequencing assay. Protein- and RNA splicing-dedicated in silico analyses were performed for all variants of unknown significance (VUS). Variants predicted as the ones most likely affecting pre-mRNA splicing were experimentally analyzed in a minigene assay. RESULTS: We identified 48 women who were tested negative for their family’s path_BRCA1 (n = 13) or path_BRCA2 (n = 35) variants. Pathogenic variants in the ATM, BRCA2, MSH6 and MUTYH genes were found in 10% (5/48) of the cases, of whom 15% (2/13) were from path_BRCA1 and 9% (3/35) from path_BRCA2 families. Out of the 26 unique VUS, 3 (12%) were predicted to affect RNA splicing (APC c.721G > A, MAP3K1 c.764A > G and MSH2 c.815C > T). However, by using a minigene, assay we here show that APC c.721G > A does not cause a splicing defect, similarly to what has been recently reported for the MAP3K1 c.764A > G. The MSH2 c.815C > T was previously described as causing partial exon skipping and it was identified in this work together with the path_BRCA2 c.9382C > T (p.R3128X). CONCLUSION: All women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13053-018-0086-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-15 /pmc/articles/PMC5769521/ /pubmed/29371908 http://dx.doi.org/10.1186/s13053-018-0086-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dominguez-Valentin, Mev
Evans, D. Gareth R.
Nakken, Sigve
Tubeuf, Hélène
Vodak, Daniel
Ekstrøm, Per Olaf
Nissen, Anke M.
Morak, Monika
Holinski-Feder, Elke
Martins, Alexandra
Møller, Pål
Hovig, Eivind
Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title_full Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title_fullStr Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title_full_unstemmed Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title_short Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds
title_sort genetic variants of prospectively demonstrated phenocopies in brca1/2 kindreds
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769521/
https://www.ncbi.nlm.nih.gov/pubmed/29371908
http://dx.doi.org/10.1186/s13053-018-0086-0
work_keys_str_mv AT dominguezvalentinmev geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT evansdgarethr geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT nakkensigve geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT tubeufhelene geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT vodakdaniel geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT ekstrømperolaf geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT nissenankem geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT morakmonika geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT holinskifederelke geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT martinsalexandra geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT møllerpal geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds
AT hovigeivind geneticvariantsofprospectivelydemonstratedphenocopiesinbrca12kindreds